Literature DB >> 12145453

A comprehensive review of proton magnetic resonance spectroscopy studies in dementia and Parkinson's disease.

M J Firbank1, R M Harrison, J T O'Brien.   

Abstract

We reviewed the literature of proton magnetic resonance spectroscopy (MRS) in dementia and Parkinson's disease (PD) and quantitatively compared the reported values of the markers N-acetyl aspartate (NAA), choline, and myo-Inositol between control and disease groups. We analysed a total of 27 reports in dementia. Combining the quantitative data from these showed a relative decrease of 15% in NAA level in the temporal lobe tissue in patients with Alzheimer's disease (AD) compared with controls. The rest of the brain showed a seemingly uniform 10% decrease in NAA levels in AD compared with controls. myo-Inositol was raised by about 15%, again uniformly throughout the brain, but there was no evidence for changed levels of choline. We found 15 reports of MRS in PD, which show a small decrease (5%) in the NAA level in the lentiform nucleus compared with controls. In progressive supranuclear palsy (PSP), there is a greater decrease in NAA levels in the frontal region and the lentiform nucleus. This may aid in the diagnosis of PSP. Further research is needed to determine spectroscopic changes in other dementias, to monitor how markers change with disease progression and to establish clinical utility. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12145453     DOI: 10.1159/000064927

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  32 in total

1.  T1rho (T1ρ) MR imaging in Alzheimer's disease and Parkinson's disease with and without dementia.

Authors:  Mohammad Haris; Anup Singh; Kejia Cai; Christos Davatzikos; John Q Trojanowski; Elias R Melhem; Christopher M Clark; Arijitt Borthakur
Journal:  J Neurol       Date:  2010-10-07       Impact factor: 4.849

Review 2.  Neuroimaging in Parkinson's disease.

Authors:  A Jon Stoessl
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

Review 3.  Magnetic resonance imaging of myelin.

Authors:  Cornelia Laule; Irene M Vavasour; Shannon H Kolind; David K B Li; Tony L Traboulsee; G R Wayne Moore; Alex L MacKay
Journal:  Neurotherapeutics       Date:  2007-07       Impact factor: 7.620

4.  Profiles of brain oxidative damage, ventricular alterations, and neurochemical metabolites in the striatum of PINK1 knockout rats as functions of age and gender: Relevance to Parkinson disease.

Authors:  Xiaojia Ren; Angela Hinchie; Aaron Swomley; David K Powell; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2019-08-08       Impact factor: 7.376

5.  Age-related Brain Metabolic Changes up to Seventh Decade in Healthy Humans : Whole-brain Magnetic Resonance Spectroscopic Imaging Study.

Authors:  Helen Maghsudi; Martin Schütze; Andrew A Maudsley; Mete Dadak; Heinrich Lanfermann; Xiao-Qi Ding
Journal:  Clin Neuroradiol       Date:  2019-07-26       Impact factor: 3.649

6.  Plasma metabolic profiling analysis of neurotoxicity induced by oxaliplatin using metabonomics and multivariate data analysis.

Authors:  Yanyan Xu; Yiwei Zhao; Xuejun Guo; Yubo Li; Yanjun Zhang
Journal:  Toxicol Res (Camb)       Date:  2018-04-27       Impact factor: 3.524

7.  Magnetic resonance spectroscopy and neurocognitive dysfunction in obstructive sleep apnea before and after CPAP treatment.

Authors:  Fergal J O'Donoghue; R Mark Wellard; Peter D Rochford; Andrew Dawson; Maree Barnes; Warren R Ruehland; Melinda L Jackson; Mark E Howard; Robert J Pierce; Graeme D Jackson
Journal:  Sleep       Date:  2012-01-01       Impact factor: 5.849

8.  Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI).

Authors:  Susanne G Mueller; Michael W Weiner; Leon J Thal; Ronald C Petersen; Clifford R Jack; William Jagust; John Q Trojanowski; Arthur W Toga; Laurel Beckett
Journal:  Alzheimers Dement       Date:  2005-07       Impact factor: 21.566

9.  Clinical and molecular characterisation of a Parkinson family with a novel PINK1 mutation.

Authors:  Jügen Prestel; Klaus Gempel; Till-Karsten Hauser; Katherine Schweitzer; Holger Prokisch; Uwe Ahting; Dirk Freudenstein; Eva Bueltmann; Thomas Naegele; Daniela Berg; Thomas Klopstock; Thomas Gasser
Journal:  J Neurol       Date:  2008-02-21       Impact factor: 4.849

10.  Metabolic profiling of Parkinson's disease: evidence of biomarker from gene expression analysis and rapid neural network detection.

Authors:  Shiek Ssj Ahmed; Winkins Santosh; Suresh Kumar; Hema T Thanka Christlet
Journal:  J Biomed Sci       Date:  2009-07-13       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.